Silence Therapeutics
Silence Therapeutics is a biotechnology company based in London, UK, specializing in the research and development of RNA therapeutics. The company focuses on crafting short interfering RNA (siRNA) molecules that activate the RNA interference (RNAi) pathway, leading to the degradation of specific messenger RNAs. Silence Therapeutics is advancing several product candidates, including SLN124 for iron overload disorders, SLN360 targeting cardiovascular diseases linked to high lipoprotein levels, and SLN500 aimed at treating complement-mediated diseases. The company leverages its proprietary genetic toolkit to modulate gene expression and has established strategic collaborations, notably with AstraZeneca, to develop small interfering RNA therapeutics for various diseases. Formerly known as SR Pharma, Silence Therapeutics has evolved to utilize its innovative technology to create therapeutic effects within the body's own cells.
Arrowhead Pharmaceuticals is a biotechnology company based in Pasadena, California, focused on developing innovative therapies for intractable diseases with a genetic basis, particularly those involving the overproduction of specific proteins. The company's pipeline includes several RNA interference (RNAi) therapeutic candidates, such as ARO-AAT for liver diseases linked to alpha-1 antitrypsin deficiency, ARO-APOC3 for hypertriglyceridemia, and ARO-HIF2 for clear cell renal cell carcinoma. Other candidates in various stages of clinical trials aim to address conditions like chronic obstructive pulmonary disease, COVID-19, and cardiovascular diseases. Arrowhead has established collaboration agreements with Janssen Pharmaceuticals and Takeda Pharmaceuticals to further advance its RNAi therapeutics targeting liver-expressed genes. The company, originally founded as Arrowhead Research Corporation in 1989, rebranded in 2016 to reflect its focus on pharmaceutical development.
Private biotechnology company that develops systematic RNA interference (RNAi) therapeutics for the treatment of serious diseases with an initial focus on oncology. The company's expertise in drug development and delivery serves as the foundation of Intradigm RNAi platform. In particular, the company proprietary RNAi Nanoplex delivery technology is unique in its ability to enable the targeted delivery of RNAi therapeutics to specific tissues through systemic administration of the drug product.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.